Survey of ophthalmology最新文献_第2页

Choroidal nevi and melanoma doubling times and implications for delays in treatment: A systematic review and meta-analysis. 脉络膜痣和黑色素瘤的倍增时间及其对延迟治疗的影响：系统回顾和荟萃分析。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-09-28 DOI: 10.1016/j.survophthal.2024.09.004

Gustav Stålhammar, Anna Hagström, Malin Ermedahl Conradi, Pete A Williams

{"title":"Choroidal nevi and melanoma doubling times and implications for delays in treatment: A systematic review and meta-analysis.","authors":"Gustav Stålhammar, Anna Hagström, Malin Ermedahl Conradi, Pete A Williams","doi":"10.1016/j.survophthal.2024.09.004","DOIUrl":"10.1016/j.survophthal.2024.09.004","url":null,"abstract":"The prognostic implications of delaying treatment for primary uveal melanoma remain debated. We evaluate the impact of choroidal nevi and melanoma doubling times on metastatic death incidence and compare this impact across different tumor sizes. A literature search in PubMed and Web of Science targeted studies published after 1980 that quantified growth rates for choroidal or ciliochoroidal melanomas or nevi based on serial imaging found 199 melanomas and 87 growing nevi from 5 studies. In a random effects model, the estimated average volume doubling time was 360 days across all patients, with doubling times of 717, 421, and 307 days for small, medium, and large melanomas, respectively, and 6392 days for growing nevi. A mixed-effects model estimated that the 10-year incidence of metastatic death increases by 0.3, 1.8, and 4.0 percentage points every month a small, medium, and large melanoma remains untreated. Similar results were produced using two independent sources for survival data. These findings suggest that choroidal melanoma growth follows a super-exponential curve, with larger tumors exhibiting shorter doubling times. Based on these growth rates, delaying definitive treatment increases the risk of metastatic death by nearly zero to several percentage points per month, depending on tumor size.","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evidence-based guidelines for drug dosing in intravitreal injections in silicone oil-filled eyes: Pharmacokinetics, safety, and optimal dosage. 基于证据的硅油填充眼玻璃体内注射药物剂量指南：药代动力学、安全性和最佳剂量。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-09-27 DOI: 10.1016/j.survophthal.2024.09.006

Lorenzo Ferro Desideri, Peng Yong Sim, Enrico Bernardi, Karin Paschon, Janice Roth, Adrian T Fung, Xia Ni Wu, Hung-Da Chou, Robert Henderson, Edmund Tsui, Maria Berrocal, Jay Chhablani, Charles C Wykoff, Chui Ming Gemmy Cheung, Giuseppe Querques, Gustavo Barreto Melo, Yousif Subhi, Anat Loewenstein, Jens Folke Kiilgaard, Martin Zinkernagel, Rodrigo Anguita

{"title":"Evidence-based guidelines for drug dosing in intravitreal injections in silicone oil-filled eyes: Pharmacokinetics, safety, and optimal dosage.","authors":"Lorenzo Ferro Desideri, Peng Yong Sim, Enrico Bernardi, Karin Paschon, Janice Roth, Adrian T Fung, Xia Ni Wu, Hung-Da Chou, Robert Henderson, Edmund Tsui, Maria Berrocal, Jay Chhablani, Charles C Wykoff, Chui Ming Gemmy Cheung, Giuseppe Querques, Gustavo Barreto Melo, Yousif Subhi, Anat Loewenstein, Jens Folke Kiilgaard, Martin Zinkernagel, Rodrigo Anguita","doi":"10.1016/j.survophthal.2024.09.006","DOIUrl":"10.1016/j.survophthal.2024.09.006","url":null,"abstract":"We evaluate the pharmacokinetics, safety, and optimal dosages of intravitreal agents in silicone oil (SO)-filled eyes, addressing challenges in administering such therapies. We assessed the pharmacological properties and safety profiles of intravitreal drugs in SO-filled eyes, deriving conclusions and guidance from available literature and expert consensus. Preclinical data suggest comparable half-lives of anti-vascular endothelial growth factoragents in SO-filled eyes, but clinical evidence is mainly from case reports and small series. Available research prioritizes standard dosages, particularly for bevacizumab (1.25 mg), supported by stronger evidence than aflibercept (2 mg) or ranibizumab (0.5 mg). Intravitreal steroids, especially dexamethasone at 0.7 mg, show efficacy and safety, while evidence for fluocinolone acetonide at 0.19 mg is limited. Intravitreal methotrexate has been reported at the dosage of 250-400 μg, with keratitis as the primary expected side effect. Case reports indicate tolerability of standard dosages of antivirals (foscarnet 1.2-2.4 mg/0.1 mL, ganciclovir 4 mg/0.1 mL) and the antibiotic combination piperacillin/tazobactam (250 μg/0.1 mL). We offer guidance based on current, but limited, literature. Standard dosage of intravitreal agents should be carefully considered, along with close monitoring for potential side effects, which should be discussed with patients.","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenging corneal diseases and microRNA expression: Focus on rare diseases and new therapeutic frontiers. 挑战性角膜疾病与 miRNA 表达：聚焦罕见疾病和新的治疗前沿。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-09-27 DOI: 10.1016/j.survophthal.2024.09.002

Ludovico Alisi, Francesca Giovannetti, Marta Armentano, Luca Lucchino, Alessandro Lambiase, Alice Bruscolini

{"title":"Challenging corneal diseases and microRNA expression: Focus on rare diseases and new therapeutic frontiers.","authors":"Ludovico Alisi, Francesca Giovannetti, Marta Armentano, Luca Lucchino, Alessandro Lambiase, Alice Bruscolini","doi":"10.1016/j.survophthal.2024.09.002","DOIUrl":"10.1016/j.survophthal.2024.09.002","url":null,"abstract":"MicroRNAs (miRNAs) function as posttranscriptional regulators of gene expression by targeting specific messenger RNA (mRNA). This interaction modulates mRNA stability or translational efficiency, ultimately impacting the level of protein production. Emerging evidence suggests that miRNAs act as critical regulators in corneal diseases. These molecules finetune key processes like cell proliferation, differentiation, inflammation, and wound healing. We reviewed the literature to understand the role that miRNAs may play in the development of challenging and poorly understood corneal diseases. We focused on vernal keratoconjunctivitis, neurotrophic keratitis, keratoconus, Fuchs endothelial corneal dystrophy, and limbal stem cell deficiency. Furthermore, we explored currently studied agonists or antagonists of miRNAs that share similar pathways with ocular diseases and could be employed in ophthalmology in the future. The distinct miRNA expression profiles observed in different ocular surface pathologies, combined with the remarkable stability and relatively easy access of miRNA sampling in biofluids, present possibilities for the development of noninvasive and highly accurate diagnostic tools. Furthermore, comprehending miRNA's pathophysiological role could open new frontiers to a more comprehensive understanding of the pathophysiology underlying ocular surface diseases, thereby paving the way for the creation of novel therapeutic strategies.","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vitreous cortex remnants in patients with rhegmatogenous retinal detachment: A systematic review and meta-analysis. 流变性视网膜脱离患者的玻璃体皮质残留：系统回顾与元分析》。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-09-26 DOI: 10.1016/j.survophthal.2024.09.008

Andrea D'Albenzio, Klara Komici, Marzia Affatato, Angela Maria Castelluzzo, Serena De Turris, Emanuele Tonti, Germano Guerra, Roberto dell'Omo

{"title":"Vitreous cortex remnants in patients with rhegmatogenous retinal detachment: A systematic review and meta-analysis.","authors":"Andrea D'Albenzio, Klara Komici, Marzia Affatato, Angela Maria Castelluzzo, Serena De Turris, Emanuele Tonti, Germano Guerra, Roberto dell'Omo","doi":"10.1016/j.survophthal.2024.09.008","DOIUrl":"10.1016/j.survophthal.2024.09.008","url":null,"abstract":"The terminology \"vitreous cortex remnants\" (VCR) indicates the outermost lamellae of vitreous cortex that remains attached to the retinal surface as a consequence of vitreoschisis. The relevance of VCR removal in eyes with rhegmatogenous retinal detachment (RRD) is unknown. We conducted a review from January 1, 2000, to July 30, 2023, examining 1493 eyes. Outcome measures included: prevalence of VCR, relationship between VCR and detachment recurrence due to proliferative vitreoretinopathy (PVR), and relationship between VCR and epiretinal membrane (ERM) formation. A meta-analysis was performed with data reported as odds ratios (OR) or mean difference and 95 % confidence intervals. Prevalence of macular and peripheral VCR was 53.4 and 46.8, respectively, with an overall VCR prevalence of 50.8 (95 % CI 42.6, 59.1) Given the scarcity of available data, meta-analysis regarding the relationship between peripheral VCR and redetachment due to PVR was not feasible. The odds of developing ERM were not statistically different between eyes that had had macular VCR removal vs. eyes that had not (log OR -0.08 [95 % CI -1.06, 0.89 p= 0.89]. Additional prospective studies are required to verify whether removal of VCR may reduce the odds of recurrence of RRD due to PVR and the development of ERM.","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Focal choroidal excavation: Review and updated pathogenesis. 局灶性脉络膜挖掘：回顾与最新发病机制。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-09-25 DOI: 10.1016/j.survophthal.2024.09.010

Chunyan Lei, Zhongping Lv, Rui Hua, Jianan Duan, Meixia Zhang

引用次数: 0

Corneal densitometry: A new evaluation indicator for corneal diseases. 角膜密度测量：角膜疾病的新评估指标。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-09-24 DOI: 10.1016/j.survophthal.2024.09.007

Qing Yang, Gen Ju, Yuxi He

引用次数: 0

Unveiling the Therapeutic Potential and Mechanisms of Stanniocalcin-1 in Retinal Degeneration. 揭示 Stanniocalcin-1 在视网膜变性中的治疗潜力和机制。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-09-11 DOI: 10.1016/j.survophthal.2024.08.001

Kexin Wang,Yashuang Liu,Siyu Li,Na Zhao,Fangyuan Qin,Ye Tao,Zongming Song

{"title":"Unveiling the Therapeutic Potential and Mechanisms of Stanniocalcin-1 in Retinal Degeneration.","authors":"Kexin Wang,Yashuang Liu,Siyu Li,Na Zhao,Fangyuan Qin,Ye Tao,Zongming Song","doi":"10.1016/j.survophthal.2024.08.001","DOIUrl":"https://doi.org/10.1016/j.survophthal.2024.08.001","url":null,"abstract":"Retinal degeneration (RD) is a group of ocular diseases characterized by progressive photoreceptor apoptosis and visual impairment. Mitochondrial malfunction, excessive oxidative stress, and chronic activation of neuroglia collectively contribute to the development of RD. Currently, there is a lack of efficacious therapeutic interventions for RD. Stanniocalcin-1 (STC-1) is a promising candidate molecule to decelerate photoreceptor cell death. STC-1 is a secreted calcium/phosphorus regulatory protein that exerts diverse protective effects. Accumulating evidence suggests that STC-1 protects retinal cells from ischemic injury, oxidative stress, and excessive apoptosis through enhancing the expression of uncoupling protein-2 (UCP-2). Furthermore, STC-1 exerts its antiinflammatory effects by inhibiting the activation of microglia and macrophages, as well as the synthesis and secretion of proinflammatory cytokines, such as TNF-α, IL-1, and IL-6. By employing these mechanisms, STC-1 effectively shields the retinal photoreceptors and optic nerve, thereby slowing down the progression of RD. This review summarizes the STC-1 mediated therapeutic effects on the degenerating retina, with a particular focus on its underlying mechanisms. These findings highlight that STC-1 may act as a versatile molecule to treat degenerative retinopathy. Further research on STC-1 is imperative to establish the optimal protocols for its clinical use.","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142250844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diabetic uveopathy. 糖尿病葡萄膜病变

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-09-10 DOI: 10.1016/j.survophthal.2024.09.001

Wenyu Yang, Ruoxin Ren, Yi Xie, Junhui Wang, Huaijin Guan, Min Ji

{"title":"Diabetic uveopathy.","authors":"Wenyu Yang, Ruoxin Ren, Yi Xie, Junhui Wang, Huaijin Guan, Min Ji","doi":"10.1016/j.survophthal.2024.09.001","DOIUrl":"https://doi.org/10.1016/j.survophthal.2024.09.001","url":null,"abstract":"Diabetes can involve several ocular structures -- including the cornea, lens, and retina -- and cause vascular and neural changes in these tissues. Although retinopathy is the most common ocular complication of diabetes, uveopathy can also be observed. This includes vascular, neural, muscular, and basement membrane changes. The main clinical manifestations of diabetic uveopathy are anterior uveitis and abnormal pupillary dynamics. Fluorescein angiography, optical coherence tomography, and optical coherence tomography angiography are ideal for the imaging of vascular changes of the iris and choroid, while dynamic pupillometry is a simple screening tool to detect neuropathy. Additionally, ultrasound biomicroscopy can provide clear images of the ciliary body. Iris abnormalities, primarily angiopathy and neuropathy, can appear as alterations in vascular diameter, neovascularization, and abnormal pupillary dynamics. Choroidal abnormalities primarily affect blood vessels, including alterations in vascular diameter, microaneurysm formation, and neovascularization. The abnormal manifestations in the ciliary body include a decrease in vessel count, alterations in their diameter, isolated angiomatous dilatation, and diffuse thickening of the basal membrane of the pigment epithelium.","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142295901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety protocols, precautions, and countermeasures aboard the International Space Station (ISS) to prevent ocular injury. 国际空间站（ISS）上防止眼部损伤的安全协议、预防措施和对策。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-09-03 DOI: 10.1016/j.survophthal.2024.08.005

Alex Suh, Sarah Ditelberg, Jonathan J Szeto, Divy Kumar, Joshua Ong, C Robert Gibson, Thomas H Mader, Ethan Waisberg, Andrew G Lee

{"title":"Safety protocols, precautions, and countermeasures aboard the International Space Station (ISS) to prevent ocular injury.","authors":"Alex Suh, Sarah Ditelberg, Jonathan J Szeto, Divy Kumar, Joshua Ong, C Robert Gibson, Thomas H Mader, Ethan Waisberg, Andrew G Lee","doi":"10.1016/j.survophthal.2024.08.005","DOIUrl":"https://doi.org/10.1016/j.survophthal.2024.08.005","url":null,"abstract":"The International Space Station (ISS) is a $100 billion epicenter of human activity in the vacuum of space, displaying mankind's collective endeavor to explore the cosmic frontier. Even within the marvels of technological sophistication aboard the ISS, the human eye remains a highly vulnerable structure. In the absence of multiple layers of protection and risk assessments, crewmembers would face a substantial increase in vulnerability to ocular injury. Aside from stringent preflight screening criteria for astronauts, the ISS is equipped with ophthalmic medications, environmental control and life support systems (e.g., humidity regulation, carbon dioxide removal, pressurized device regulators), and radiation protection to reduce ocular injury. Moreover, additional countermeasures are currently being developed to mitigate the effects of spaceflight-associated neuro-ocular syndrome (SANS) and lunar dust toxicity for the Artemis Program missions. The success of future endeavors hinges not only on continued technological innovation, but also respecting the intricate interplay between human physiology and the extraterrestrial environments. Establishing habitations on the Moon and Mars, as well as NASA's Gateway Program (humanity's first space station around the Moon), will introduce a new set of challenges, underscoring the necessity for continuous insights into ocular health in space. We discuss the safety protocols, precautions, and countermeasures implemented on the ISS to prevent ocular injury - an aspect often overshadowed by the grandeur of space exploration.","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Looking beyond blurred margins 临床挑战：超越模糊边缘。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-09-01 DOI: 10.1016/j.survophthal.2024.03.001

{"title":"Looking beyond blurred margins","authors":"","doi":"10.1016/j.survophthal.2024.03.001","DOIUrl":"10.1016/j.survophthal.2024.03.001","url":null,"abstract":"<div>A 60-year-old man presented to an outside ophthalmology clinic with 1 month of progressive vision loss in the right eye (OD). Right optic disc edema was noted. Brain and orbit magnetic resonance imaging revealed right optic nerve and left occipital lobe enhancement. He was seen initially by neurology and neurosurgery and subsequently referred to neuro-ophthalmology for consideration of optic nerve biopsy. He was seen 3 months after his initial symptom onset where vision was light perception OD and a relative afferent pupillary defect with optic nerve edema. OS was unremarkable. A lumbar puncture with flow cytometry was negative for multiple sclerosis and lymphoma. At his oculoplastic evaluation for optic nerve biopsy, his vision was noted to be no light perception OD. Optic nerve biopsy demonstrated non-caseating granulomatous inflammation consistent with neurosarcoidosis. The patient was started on high-dose oral steroids with improvement of disc edema, as well as significant improvement in optic nerve and intracranial parenchymal enhancement, although his vision never improved.</div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0039625724000237/pdfft?md5=46cfb91707f9ebc8b5ffcb891783aae9&pid=1-s2.0-S0039625724000237-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140137304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0